Live Birth Following Uterine Transplantation From a Nulliparous Deceased Donor.


Journal

Transplantation
ISSN: 1534-6080
Titre abrégé: Transplantation
Pays: United States
ID NLM: 0132144

Informations de publication

Date de publication:
01 05 2021
Historique:
pubmed: 17 6 2020
medline: 27 7 2021
entrez: 17 6 2020
Statut: ppublish

Résumé

Nulliparous uterine grafts have never been used in uterus transplantation (UTx), possibly due to presumed infertility. Our objective was to verify the feasibility of nulliparous uterine graft transplantation. The Czech Uterus Transplant Trial (registered under ClinicalTrials.gov, identifier NCT03277430) is a 2-arm trial comparing the efficacy of deceased donor (DD) versus live-donor uterus transplant (10 patients in both arms). A 25-year-old patient suffering from inborn absolute uterine factor infertility underwent a DD uterus transplant. The donor was a 20-year-old nulliparous brain-dead donor. The transplant procedure was uneventful. The posttransplant period was complicated by (1) recurrent episodes of acute cellular rejection, (2) neutropenia necessitating the administration of granulocyte colony-stimulating factor, (3) vaginal anastomotic stenosis treated with the insertion of a self-expanding stent, (4) the concurrence of Clostridium difficile colitis and acute appendicitis, and (5) temporary renal function impairment of a combined cause. Two years after the UTx, after the fourth embryo transfer, the patient became pregnant. Apart from gestational diabetes mellitus, the pregnancy was uneventful. Due to preterm contractions, delivery was achieved via caesarean section at gestational age 34 + 6 years. The postoperative course was uneventful for both the mother and the newborn. Herein, we report the first live birth after a DD UTx in Europe. This report provides a proof of concept that nulliparous uteri may present a suitable source of uterine grafts for UTx. Stenting may serve as a feasible treatment method for vaginal anastomotic stenosis.

Sections du résumé

BACKGROUND
Nulliparous uterine grafts have never been used in uterus transplantation (UTx), possibly due to presumed infertility. Our objective was to verify the feasibility of nulliparous uterine graft transplantation.
METHODS
The Czech Uterus Transplant Trial (registered under ClinicalTrials.gov, identifier NCT03277430) is a 2-arm trial comparing the efficacy of deceased donor (DD) versus live-donor uterus transplant (10 patients in both arms). A 25-year-old patient suffering from inborn absolute uterine factor infertility underwent a DD uterus transplant. The donor was a 20-year-old nulliparous brain-dead donor.
RESULTS
The transplant procedure was uneventful. The posttransplant period was complicated by (1) recurrent episodes of acute cellular rejection, (2) neutropenia necessitating the administration of granulocyte colony-stimulating factor, (3) vaginal anastomotic stenosis treated with the insertion of a self-expanding stent, (4) the concurrence of Clostridium difficile colitis and acute appendicitis, and (5) temporary renal function impairment of a combined cause. Two years after the UTx, after the fourth embryo transfer, the patient became pregnant. Apart from gestational diabetes mellitus, the pregnancy was uneventful. Due to preterm contractions, delivery was achieved via caesarean section at gestational age 34 + 6 years. The postoperative course was uneventful for both the mother and the newborn.
CONCLUSIONS
Herein, we report the first live birth after a DD UTx in Europe. This report provides a proof of concept that nulliparous uteri may present a suitable source of uterine grafts for UTx. Stenting may serve as a feasible treatment method for vaginal anastomotic stenosis.

Identifiants

pubmed: 32541565
pii: 00007890-202105000-00023
doi: 10.1097/TP.0000000000003346
doi:

Banques de données

ClinicalTrials.gov
['NCT03277430']

Types de publication

Case Reports Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1077-1081

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Déclaration de conflit d'intérêts

The authors declare no conflicts of interest.

Références

Testa G, McKenna GJ, Gunby RT Jr, et al. First live birth after uterus transplantation in the United States. Am J Transplant. 2018;18:1270–1274.
Brännström M, Johannesson L, Bokström H, et al. Livebirth after uterus transplantation. Lancet. 2015;385:607–616.
Ejzenberg D, Andraus W, Baratelli Carelli Mendes LR, et al. Livebirth after uterus transplantation from a deceased donor in a recipient with uterine infertility. Lancet. 2019;392:2697–2704.
Chmel R, Novackova M, Janousek L, et al. Revaluation and lessons learned from the first 9 cases of a Czech uterus transplantation trial: four deceased donor and 5 living donor uterus transplantations. Am J Transplant. 2019;19:855–864.
Chmel R, Pastor Z, Novackova M, et al. Clinical pregnancy after deceased donor uterus transplantation: lessons learned and future perspectives. J Obstet Gynaecol Res. 2019;45:1458–1465.
Froněk J, Janousek L, Chmel R. Deceased donor uterus retrieval—the first Czech experience. Rozhl Chir. 2016;95:312–316.
Richards EG, Flyckt R, Tzakis A, et al. Uterus transplantation: organ procurement in a deceased donor model. Fertil Steril. 2018;110:183.
Flyckt R, Falcone T, Quintini C, et al. First birth from a deceased donor uterus in the United States: from severe graft rejection to successful cesarean delivery. Am J Obstet Gynecol. 2020;223:143–151. doi: 10.1016/j.ajog.2020.03.001
doi: 10.1016/j.ajog.2020.03.001
Baker VL, Jones CE, Cometti B, et al. Factors affecting success rates in two concurrent clinical IVF trials: an examination of potential explanations for the difference in pregnancy rates between the United States and Europe. Fertil Steril. 2010;94:1287–1291.
Ozkan O, Akar ME, Ozkan O, et al. Preliminary results of the first human uterus transplantation from a multiorgan donor. Fertil Steril. 2013;99:470–476.
Erman Akar M, Ozkan O, Aydinuraz B, et al. Clinical pregnancy after uterus transplantation. Fertil Steril. 2013;100:1358–1363.
Rutstein SO, Shah IH. Infecundity, Infertility, and Childlessness in Developing Countries. 2004. ORC Macro/World Health Organization14–15.
Kotton CN. Migrating from universal to personalized prevention: predicting the risk of cytomegalovirus infection after organ transplantation. Transplantation. 2018;102:1787–1788.

Auteurs

Jiri Fronek (J)

Transplant Surgery Department, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Second Faculty of Medicine, Charles University, Prague, Czech Republic.
First Faculty of Medicine, Charles University, Prague, Czech Republic.
Department of Anatomy, Second Faculty of Medicine, Charles University, Prague, Czech Republic.

Libor Janousek (L)

Transplant Surgery Department, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
First Faculty of Medicine, Charles University, Prague, Czech Republic.

Jakub Kristek (J)

Transplant Surgery Department, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Department of Anatomy, Second Faculty of Medicine, Charles University, Prague, Czech Republic.

Jaroslav Chlupac (J)

Transplant Surgery Department, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Second Faculty of Medicine, Charles University, Prague, Czech Republic.
Department of Anatomy, Second Faculty of Medicine, Charles University, Prague, Czech Republic.

Marek Pluta (M)

Department of Obstetrics and Gynaecology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.

Robert Novotny (R)

Transplant Surgery Department, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.

Jana Maluskova (J)

Department of Clinical and Transplant Pathology, Institute of Clinical and Experimental Medicine, Prague, Czech Republic.

Michael Olausson (M)

Department of Transplantation Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH